UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)
(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
0209.1003

Total Pages in this Submission

TO THE COMMISSIONER FOR PATENTS
Mail Stop Patent Application
P.O. Box 1450
Alexandria, VA 22313-1450

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

USE OF CYCLOPHILIN AS ANTIOXIDANT AND PREVENTION OF CYCLOSPORIN A-INDUCED TOXICITY IN CELL TRANSPLANTATION BY OVEREXPRESSION OF CYCLOPHILIN

and invented by:

LEE, Jin Hwa; HONG, Feng and HA, Joo Hun

If a **CONTINUATION APPLICATION,** *check appropriate box and supply the requisite information:*

☐ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: _____

Which is a:

☐ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: _____

Which is a:

☐ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: _____

Enclosed are:

Application Elements

1. ☒ Filing fee as calculated and transmitted as described below

2. ☒ Specification having _____46_____ pages and including the following:

    a. ☒ Descriptive Title of the Invention

    b. ☐ Cross References to Related Applications *(if applicable)*

    c. ☐ Statement Regarding Federally-sponsored Research/Development *(if applicable)*

    d. ☐ Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix

    e. ☒ Background of the Invention

    f. ☒ Brief Summary of the Invention

    g. ☒ Brief Description of the Drawings *(if filed)*

    h. ☒ Detailed Description

    i. ☒ Claim(s) as Classified Below

    j. ☒ Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL **(Small Entity)** *(Only for new nonprovisional applications under 37 CFR 1.53(b))*	Docket No. 0209.1003
	Total Pages in this Submission

Application Elements (Continued)

3. ☒ Drawing(s) *(when necessary as prescribed by 35 USC 113)*

    a. ☒ Formal   Number of Sheets   24

    b. ☐ Informal   Number of Sheets

4. ☒ Oath or Declaration

    a. ☐ Newly executed *(original or copy)*   ☒ Unexecuted

    b. ☐ Copy from a prior application (37 CFR 1.63(d)) *(for continuation/divisional application only)*

    c. ☒ With Power of Attorney   ☐ Without Power of Attorney

    d. ☐ *DELETION OF INVENTOR(S)*
        Signed statement attached deleting inventor(s) named in the prior application,
        see 37 C.F.R. 1.63(d)(2) and 1.33(b).

5. ☐ Incorporation By Reference *(usable if Box 4b is checked)*
    The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)

7. ☐ Application Data Sheet (See 37 CFR 1.76)

8. ☒ Nucleotide and/or Amino Acid Sequence Submission *(if applicable, all must be included)*

    a. ☒ Computer Readable Form (CFR)

    b. ☒ Specification Sequence Listing on:

         i. ☐ CD-ROM or CD-R (2 copies); or

         ii. ☒ Paper

    c. ☒ Statement(s) Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

9. ☐ Assignment Papers (cover sheet & document(s))

10. ☐ 37 CFR 3.73(B) Statement (when there is an assignee)

11. ☐ English Translation Document (if applicable)

12. ☒ Information Disclosure Statement/PTO-1449   ☒ Copies of IDS Citations

13. ☒ Preliminary Amendment

14. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)

15. ☒ Certified Copy of Priority Document(s) (if foreign priority is claimed)

16. ☒ Certificate of Mailing

     ☐ First Class   ☒ Express Mail *(Specify Label No.):*   **EV 327 588 067 US**

Accompanying Application Parts (Continued)

17. ☒ Applicant claims small entity status. See 37 CFR 1.27.

   ☐ (Optional) Small Entity Statement(s) - Specify Number of Statements Submitted: _____

18. ☐ Additional Enclosures *(please identify below)*:

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

19. ☐ Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

P01USML/REV06

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate		Fee
Total Claims	9	- 20 =	0	x	$9.00	$0.00
Indep. Claims	5	- 3 =	2	x	$42.00	$84.00
Multiple Dependent Claims (check if applicable) ☐						$0.00
					BASIC FEE	$375.00
OTHER FEE *(specify purpose)*						$0.00
					TOTAL FILING FEE	$459.00

☒ Credit Card Payment Authorization Form is enclosed (1 page)

☒ The Director is hereby authorized to charge and credit Deposit Account No.   02-2275
as described below.

    ☐ Charge the amount of   as filing fee.

    ☒ Credit any overpayment.

    ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.

    ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance,
       pursuant to 37 C.F.R. 1.311(b).

Dated: **August 6, 2003**

Signature

Michael N. Mercanti
Reg. No. 33,966
MUSERLIAN, LUCAS & MERCANTI, LLP
600 Third Avenue
New York, New York 10016
Phone: 212-661-8000
Fax: 212-661-8002

22856
PATENT TRADEMARK OFFICE

CC:

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)		Docket No.
Applicant(s): LEE, Jin Hwa, et al.		209.1003

Serial No. To be assigned	Filing Date Herewith	Examiner Unknown	Group Art Unit Unknown

Invention: USE OF CYCLOPHILIN AS ANTIOXIDANT AND PREVENTION OF CYCLOSPORIN A-INDUCED TOXICITY IN CELL TRANSPLANTATION BY OVEREXPRESSION OF CYCLOPHILIN

I hereby certify that the following correspondence:

Utility Patent Application Transmittal (Small Entity) (4 pages, page 4 in duplicate)

(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

August 6, 2003
(Date)

Michael N. Mercanti
(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)

EV 327 588 067 US
("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.